1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
gb263t Non-Small Cell Lung Carcinoma	Genor Biopharma Co., Ltd.	P1/2	CC (41)
gfh276 Non-Small Cell Lung Carcinoma	Genfleet Therapeutics (Shanghai) Inc.	P1/2	CC (41)
hb0036 Non-Small Cell Lung Carcinoma	Shanghai Huaota Biopharmaceutical Co., Ltd.	P1/2	CC (41)
Hbi 0201-Eso Tcrt Non-Small Cell Lung Carcinoma	Hadassah Medical Organization	P1/2	CC (41)
hj-004-02 tablets Non-Small Cell Lung Carcinoma	Tongji University	P1	CC (41)
Hs-It101 Non-Small Cell Lung Carcinoma	Qingdao Sino-Cell Biomedicine Co., Ltd.	P1	CC (41)
(-)-Hydroxyurea Methylacylfulvene Non-Small Cell Lung Carcinoma	Lantern Pharma Inc.	P1/2	CC (41)
iam1363 Non-Small Cell Lung Carcinoma	Iambic Therapeutics, Inc	P1	CC (41)
ilb2109 Non-Small Cell Lung Carcinoma	Innolake Biopharm	P1/2	CC (41)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Cytotoxic T-Lymphocyte-Associated Protein 4) (Human Monoclonal Ba3071 ?1-Chain), Disulfide With Human Monoclonal Ba3071 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	BioAtla, Inc.	P1/2	CC (41)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-2301 (96.9%) -(Ighd) -Ighj401 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (94.7%) -Igkj401 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated Non-Small Cell Lung Carcinoma	Immunitas Therapeutics	P1/2	CC (41)
Interleukin 18 (Recombinant Human Mutein Clone St-067) Non-Small Cell Lung Carcinoma	Simcha IL-18, Inc.	P1/2	CC (41)
Jab-8263 Non-Small Cell Lung Carcinoma	Jacobio Pharmaceuticals Co., Ltd.	P1/2	CC (41)
jmt203 Non-Small Cell Lung Carcinoma	Shanghai JMT-Bio Inc.	P1/2	CC (41)
js111 Non-Small Cell Lung Carcinoma	Suzhou Junjing BioSciences Co., Ltd.	P1/2	CC (41)
Lmv-12 Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P1/2	CC (41)
Mavrostobart Non-Small Cell Lung Carcinoma	Phanes Therapeutics	P1/2	CC (41)
Monoclonal Antibody Neo-201 Non-Small Cell Lung Carcinoma	Precision Biologics, Inc	P1/2	CC (41)
Mrt-2359 Non-Small Cell Lung Carcinoma	Monte Rosa Therapeutics, Inc	P1/2	CC (41)
n17350 Non-Small Cell Lung Carcinoma	Onchilles Pharma Inc	P1/2	CC (41)
ngm707 Non-Small Cell Lung Carcinoma	NGM Biopharmaceuticals, Inc	P1/2	CC (41)
Obx-115 Non-Small Cell Lung Carcinoma	Obsidian Therapeutics, Inc.	P1/2	CC (41)
Pdc*Lung01 Non-Small Cell Lung Carcinoma	PDC*line Pharma SAS	P1/2	CC (41)
pf-08046876 Non-Small Cell Lung Carcinoma	Pfizer	P1	CC (41)
Phn-012 Non-Small Cell Lung Carcinoma	Pheon Therapeutics	P1	CC (41)
Poziotinib Non-Small Cell Lung Carcinoma	Spectrum Pharmaceuticals, Inc	P3	CC (41)
Prednisone Non-Small Cell Lung Carcinoma	Biosplice Therapeutics, Inc.	P1	CC (41)
Rezatapopt Non-Small Cell Lung Carcinoma	PMV Pharmaceuticals, Inc	P1/2	CC (41)
Rtx-224 Non-Small Cell Lung Carcinoma	Rubius Therapeutics	P1/2	CC (41)
sh009 Non-Small Cell Lung Carcinoma	Nanjing Sanhome Pharmaceutical, Co., Ltd.	P1	CC (41)
Solnerstotug Non-Small Cell Lung Carcinoma	Sensei Biotherapeutics, Inc.	P1/2	CC (41)
Stk-012 Non-Small Cell Lung Carcinoma	Synthekine	P1/2	CC (41)
t3011 Non-Small Cell Lung Carcinoma	ImmVira Pharma Co. Ltd	P1/2	CC (41)
Tarlatamab Non-Small Cell Lung Carcinoma	University of Arizona	P1/2	CC (41)
tb511 Non-Small Cell Lung Carcinoma	Twinpig Biolab, Inc.	P1/2	CC (41)
tc-510 Non-Small Cell Lung Carcinoma	TCR2 Therapeutics	P1/2	CC (41)
Tgi-5 Non-Small Cell Lung Carcinoma	Hefei TG ImmunoPharma Co., Ltd.	P1	CC (41)
tj101 Non-Small Cell Lung Carcinoma	Phrontline Biopharma	P1	CC (41)
tng260 Non-Small Cell Lung Carcinoma	Tango Therapeutics, Inc.	P1/2	CC (41)
tng456 Non-Small Cell Lung Carcinoma	Tango Therapeutics, Inc.	P1/2	CC (41)
tng462 Non-Small Cell Lung Carcinoma	Tango Therapeutics, Inc.	P1/2	CC (41)
tqb2928 Non-Small Cell Lung Carcinoma	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	P1	CC (41)
Trx-221 Non-Small Cell Lung Carcinoma	Therapex Co., Ltd	P1/2	CC (41)
tt-10 Non-Small Cell Lung Carcinoma	Portage Biotech	P1/2	CC (41)
tt-4 Non-Small Cell Lung Carcinoma	Portage Biotech	P1/2	CC (41)
Tub-030 Non-Small Cell Lung Carcinoma	Tubulis GmbH	P1/2	CC (41)
Tulmimetostat Non-Small Cell Lung Carcinoma	VA Office of Research and Development	P1/2	CC (41)
ucb4594 Non-Small Cell Lung Carcinoma	Cancer Research UK	P1/2	CC (41)
Vsv-Ifnβ-Nis Non-Small Cell Lung Carcinoma	Vyriad, Inc.	P1/2	CC (41)
vt3989 Non-Small Cell Lung Carcinoma	Vivace Therapeutics, Inc	P1/2	CC (41)

Showing 701 to 750 of 1,125 assets

PreviousPage 15 of 23Next